All In Biotech

Drug Trial Radar · NCT03358875

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen

Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 805 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

805

Actual

Start

Nov 30, 2017

Primary completion

Jul 15, 2021

Study completion Jan 18, 2024

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • TislelizumabDrug

    Tislelizumab administered by intravenous (IV) infusion

  • DocetaxelDrug

    Docetaxel administered as an IV infusion over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in All Participants (Co-primary Endpoint)Time frame: From randomization to the data cutoff date of 10 August 2020; up to 32.4 months
  2. Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months

Locations

121 sites in 10 countries. Site status is shown where the registry gives one.

  • Hospital de Amor Barretos

    Barretos, Brazil

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Brazil

  • Hospital Haroldo Juacaba Instituto Do Cancer Do Ceara

    Fortaleza, Brazil

  • Oncosite Centro de Pesquisa Clinica Em Oncologia

    Ijuí, Brazil

  • Fundacao Doutor Amaral Carvalho

    Jaú, Brazil

  • Hospital Bruno Born

    Lajeado, Brazil

  • Hospital Sao Vicente de Paulo

    Passo Fundo, Brazil

  • Hgb Hospital Giovanni Battista Mae de Deus Center

    Porto Alegre, Brazil

  • Hospital Sao Lucas Da Pucrs

    Porto Alegre, Brazil

  • Hospital Nossa Senhora Da Conceicao

    Porto Alegre, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto AlegreRS, Brazil

  • Inca Instituto Nacional de Cancer

    Rio de Janeiro, Brazil

  • Nob Nucleo de Oncologia Da Bahia

    Salvador, Brazil

  • Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia

    Santo André, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

    São Paulo, Brazil

  • Umhat Deva Maria, Eood

    Burgas, Bulgaria

  • Mhat Dobrich, Ad

    Dobrich, Bulgaria

  • Mhat Dr Tota Venkova, Ad

    Gabrovo, Bulgaria

  • Complex Oncology Center Rousse Eood

    Rousse, Bulgaria

  • Mhat For Womens Health Nadezhda, Ood

    Sofia, Bulgaria

  • Acibadem City Clinic Mhat Tokuda Ead

    Sofia, Bulgaria

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Chinese Pla General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Guangzhou Institute of Respiratory Disease

    Guangzhou, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Affiliated Hospital of Zunyi Medical College

    Zunyi, Guizhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.